- Recommendation ID
Diagnostic investigations to predict treatment outcomes:- What is the prognostic value of the Hevylite assay and ratio compared with other prognostic factors and tests, including the serum-free light-chain assay and fluorescence in-situ hybridisation (FISH), in people with newly diagnosed myeloma who are starting treatment?
- Any explanatory notes
Why this is important:- Hevylite is a new assay that some studies have indicated is a useful prognostic tool. However, it is not clear how robustly it has been evaluated against other prognostic factors and tests, or whether it is an independent prognostic factor. The Hevylite assay should be evaluated in an accredited centralised laboratory independent of links with the manufacturer. Outcomes of interest are overall response, complete response, minimal residual disease, progression-free survival, overall survival and resource use.
Source guidance details
- Comes from guidance
- Myeloma: diagnosis and management
- Date issued
- February 2016
|Is this a recommendation for the use of a technology only in the context of research?||No|
|Is it a recommendation that suggests collection of data or the establishment of a register?||No|